OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wong on Recent Developments in AL Amyloidosis

September 10th 2020

Sandy Wong, MD, highlights recent developments in light chain amyloidosis.

Dr. Woyach on the Role of Acalabrutinib in CLL

September 10th 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Dr. Chiang on the Management of Immune-Related AEs in Lung Cancer

September 10th 2020

Anne Chiang, MD, PhD, discusses the management of immune-related adverse effects in lung cancer.

Dr. Visco on the Utility of Cytarabine in MCL

September 10th 2020

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Dr. Mascarenhas on the Potential Role of Pacritinib in MPNs

September 10th 2020

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLL

September 10th 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

September 9th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Woyach on Remaining Sequencing Questions in CLL

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.

Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian Cancer

September 9th 2020

Kala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.

Dr. Leslie on the Utility of BTK Inhibitors in B-Cell Malignancies

September 9th 2020

Lori A. Leslie, MD, discusses the utility of BTK inhibitors in B-cell malignancies.

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

September 9th 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Dr. Costa on Remaining Challenges With CAR T-Cell Therapy in Multiple Myeloma

September 9th 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

Dr. Burris on Recent Advances in TNBC

September 8th 2020

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses recent advancements made in the field of triple-negative breast cancer.

Dr. Hamilton on the Complex Treatment Algorithm for HER2+ Breast Cancer

September 8th 2020

Erika P. Hamilton, MD, discusses the complex treatment algorithm for HER2-positive breast cancer.

Dr. Richard on the Benefit of Adding Daratumumab to Standard-of-Care Rd in Myeloma

September 8th 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Dr. Chari on the FDA Approval of Belantamab Mafodotin in R/R Multiple Myeloma

September 8th 2020

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Dr. Pautier on the Rationale for the LMS-02 Trial in Soft Tissue Sarcoma

September 8th 2020

Patricia Pautier, MD, discusses the rationale for the phase 2 LMS-02 trial in uterine and soft tissue leiomyosarcoma.